@article{b96ecc31489e4fef84bdb0aaa3ff1434,
title = "The risks of cancer in older women with BRCA pathogenic variants: How far have we come?",
abstract = "Background: The purpose of this study was to estimate the cumulative risks of all cancers in women from 50 to 75 years of age with a BRCA1 or BRCA2 pathogenic variant. Methods: Participants were women with BRCA1 or BRCA2 pathogenic variants from 85 centers in 16 countries. Women were eligible if they had no cancer before the age of 50 years. Participants completed a baseline questionnaire and follow-up questionnaires every 2 years. Women were followed from age 50 until a diagnosis of cancer, death, age 75, or last follow-up. The risk of all cancers combined from age 50 to 75 was estimated using the Kaplan–Meier method. Results: There were 2211 women included (1470 BRCA1 and 742 BRCA2). There were 379 cancers diagnosed in the cohort between 50 and 75 years. The actuarial risk of any cancer from age 50 to 75 was 49% for BRCA1 and 43% for BRCA2. Breast (n = 186) and ovarian (n = 45) were the most frequent cancers observed. For women who had both risk-reducing mastectomy and bilateral salpingo-oophorectomy before age 50, the risk of developing any cancer between age 50 and 75 was 9%. Conclusion: Women with a BRCA1 or BRCA2 pathogenic variant have a high risk of cancer between the ages of 50 and 75 years and should be counselled appropriately.",
keywords = "BRCA1, BRCA2, breast neoplasm, fallopian tube neoplasm, ovarian neoplasm",
author = "Metcalfe, {Kelly A.} and Jacek Gronwald and Tung, {Nadine M.} and McCuaig, {Jeanna M.} and Andrea Eisen and Christine Elser and Foulkes, {William D.} and Neuhausen, {Susan L.} and Leigha Senter and Pal Moller and Louise Bordeleau and Robert Fruscio and Lea Velsher and Dana Zakalik and Olopade, {Olufunmilayo I.} and Charis Eng and Tuya Pal and Cullinane, {Carey A.} and Couch, {Fergus J.} and Joanne Kotsopoulos and Ping Sun and Jan Lubinski and Narod, {Steven A.}",
note = "Funding Information: Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible. Steven A. Narod is the recipient of a Tier I Canada Research Chair. This work was supported by a Canadian Cancer Society Research Institute (703058), and the Peter Gilgan Centre for Women's Cancers. We confirm the independence of researchers from the funders and that all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. The funding body had no role in the design of the study, collection and analysis of data and decision to publish. Funding Information: Fergus J. Couch reports consulting fees from AstraZeneca and other fees from Ambry Genetics and Qiagen Sciences LLC. Andrea Eisen reports consulting fees from Cancer Care Ontario. Christine Elser reports consulting fees from Mount Sinai Health System. Charis Eng reports grant funding from the American Cancer Society, the Breast Cancer Research Foundation, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Cancer Institute. Jeanna M. McCuaig reports consulting fees from AstraZeneca and Merck. Steven A. Narod reports grant funding from the Canadian Cancer Society Research Institute. Olufunmilayo Olopade is a fiduciary officer for CancerIQ, reports independent contracting fees from Tempus Inc, grant funding from Color Genomics, and reports stock options with 54gene. Tuya Pal reports consulting fees from Natera. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",
year = "2022",
doi = "10.1002/cncr.34615",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
}